125 related articles for article (PubMed ID: 1391738)
1. Protective effect of SR 27417, a novel PAF antagonist, on PAF- or endotoxin-induced hypotension in the rat and the guinea-pig.
Bernat A; Herbert JM; Salel V; Lespy L; Maffrand JP
J Lipid Mediat; 1992 Feb; 5(1):41-8. PubMed ID: 1391738
[TBL] [Abstract][Full Text] [Related]
2. Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist.
Herbert JM; Bernat A; Valette G; Gigo V; Lale A; LaPlace MC; Lespy L; Savi P; Maffrand JP; Le Fur G
J Pharmacol Exp Ther; 1991 Oct; 259(1):44-51. PubMed ID: 1656029
[TBL] [Abstract][Full Text] [Related]
3. Biochemical and pharmacological properties of SR 27388, a dual antioxidant and PAF receptor antagonist.
Herbert JM; Fraisse L; Bachy A; Valette G; Savi P; Laplace MC; Lassalle J; Roche B; Lale A; Keane PE
J Lipid Mediat; 1993 Aug; 8(1):31-51. PubMed ID: 8257776
[TBL] [Abstract][Full Text] [Related]
4. Effect of SR 27417, a novel PAF antagonist on antigen-induced hypotension in the rat.
Herbert JM; Bernat A; Tibiriça E
J Lipid Mediat Cell Signal; 1997 Jan; 15(2):115-23. PubMed ID: 9034959
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor.
Heuer HO; Casals-Stenzel J; Muacevic G; Weber KH
J Pharmacol Exp Ther; 1990 Dec; 255(3):962-8. PubMed ID: 2262914
[TBL] [Abstract][Full Text] [Related]
6. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents.
Terashita Z; Kawamura M; Takatani M; Tsushima S; Imura Y; Nishikawa K
J Pharmacol Exp Ther; 1992 Feb; 260(2):748-55. PubMed ID: 1738121
[TBL] [Abstract][Full Text] [Related]
7. Biological effects of the orally active platelet activating factor receptor antagonist SDZ 64-412.
Handley DA; Van Valen RG; Melden MK; Houlihan WJ; Saunders RN
J Pharmacol Exp Ther; 1988 Nov; 247(2):617-23. PubMed ID: 3183958
[TBL] [Abstract][Full Text] [Related]
8. Effect of the platelet activating factor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride on endotoxin-induced hypotension and hematological parameters in rats.
Natsume Y; Imanishi N; Koike H; Morooka S
Arzneimittelforschung; 1994 Nov; 44(11):1208-13. PubMed ID: 7848333
[TBL] [Abstract][Full Text] [Related]
9. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).
Merlos M; Giral M; Balsa D; Ferrando R; Queralt M; Puigdemont A; García-Rafanell J; Forn J
J Pharmacol Exp Ther; 1997 Jan; 280(1):114-21. PubMed ID: 8996188
[TBL] [Abstract][Full Text] [Related]
10. Effects of a platelet-activating factor antagonist, CV-3988, on different shock models in the rat.
Toth PD; Mikulaschek AW
Circ Shock; 1986; 20(3):193-203. PubMed ID: 3802423
[TBL] [Abstract][Full Text] [Related]
11. Biological effects of the new platelet-activating factor receptor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride.
Imanishi N; Murakami-Uchida M; Koike H; Natsume Y; Morooka S
Arzneimittelforschung; 1994 Mar; 44(3):317-22. PubMed ID: 8192697
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of PAF-induced systemic responses in the rat, guinea pig, dog and primate by the receptor antagonist SRI 63-441.
Handley DA; Tomesch JC; Saunders RN
Thromb Haemost; 1986 Aug; 56(1):40-4. PubMed ID: 3775689
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological activities of a novel thienodiazepine derivative as a platelet-activating factor antagonist.
Tsunoda H; Sakuma Y; Harada K; Muramoto K; Katayama S; Horie T; Shimomura N; Clark R; Miyazawa S; Okano K
Arzneimittelforschung; 1990 Nov; 40(11):1201-5. PubMed ID: 2085331
[TBL] [Abstract][Full Text] [Related]
14. Protective effect of SR 27417, a novel PAF antagonist, on lethal anaphylactic and endotoxin-induced shock in mice.
Herbert JM; Lespy L; Maffrand JP
Eur J Pharmacol; 1991 Dec; 205(3):271-6. PubMed ID: 1817964
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological profile of UK-74,505, a novel and selective PAF antagonist with potent and prolonged oral activity.
Parry MJ; Alabaster VA; Cheeseman HE; Cooper K; deSouza RN; Keir RF
J Lipid Mediat Cell Signal; 1994 Sep; 10(3):251-68. PubMed ID: 7812676
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological activities of a novel thienodiazepine derivative as a platelet-activating factor antagonist. Effects on microvascular permeability, hypotension and nephrosis.
Sakuma Y; Shirato M; Nagaoka J; Obaishi H; Tsunoda H; Katayama S; Ono H; Katayama K
Arzneimittelforschung; 1991 Dec; 41(12):1255-9. PubMed ID: 1815526
[TBL] [Abstract][Full Text] [Related]
17. Biological effect of orally active platelet-activating factor receptor antagonist SM-10661.
Komuro Y; Imanishi N; Uchida M; Morooka S
Mol Pharmacol; 1990 Sep; 38(3):378-84. PubMed ID: 2402227
[TBL] [Abstract][Full Text] [Related]
18. Effect of SR 27417 on oedema formation induced in rabbit skin by platelet-activating factor or antigen.
Herbert JM; Laplace MC; Bernat A; Salel V; Maffrand JP
Eur J Pharmacol; 1992 Jun; 216(2):175-81. PubMed ID: 1397004
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the platelet activating factor (PAF)-induced in vivo responses in rats by trans-2,5-(3,4,5-trimethoxyphenyl) tetrahydrofuran (L-652,731), a PAF receptor antagonist.
Wu MS; Biftu T; Doebber TW
J Pharmacol Exp Ther; 1986 Dec; 239(3):841-5. PubMed ID: 3795043
[TBL] [Abstract][Full Text] [Related]
20. Inhibition and reversal of endotoxin-, aggregated IgG- and paf-induced hypotension in the rat by SRI 63-072, a paf receptor antagonist.
Handley DA; Van Valen RG; Melden MK; Flury S; Lee ML; Saunders RN
Immunopharmacology; 1986 Aug; 12(1):11-6. PubMed ID: 3019921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
